Does Rallies show Form 4 insider transactions for GILD?

Yes. Rallies tracks GILD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is GILD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GILD. It does not provide personalized investment advice.

GILD (Gilead Sciences) Stock Analysis - Insider Trades

Gilead Sciences (GILD) is a publicly traded Healthcare sector company. As of May 20, 2026, GILD trades at $129.54 with a market cap of $160.99B and a P/E ratio of 17.61. GILD moved +0.10% today. Year to date, GILD is +7.32%; over the trailing twelve months it is +22.93%. Its 52-week range spans $81.83 to $157.29. Analyst consensus is strong buy with an average price target of $159.83. Rallies surfaces GILD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading GILD stock inside the company?

Recent GILD insider activity includes Dickinson Andrew D sold 3.00K, Mercier Johanna sold 7.75K, Mercier Johanna sold 11.18K, Mercier Johanna sold 8.37K, and Mercier Johanna sold 700. Rallies tracks insider transaction dates, shares, prices, and estimated values.

GILD Key Metrics

Key financial metrics for GILD
Metric	Value
Price	$129.54
Market Cap	$160.99B
P/E Ratio	17.61
EPS	$7.42
Dividend Yield	0.82%
52-Week High	$157.29
52-Week Low	$81.83
Volume	3.70M
Avg Volume	0
Revenue (TTM)	$29.74B
Net Income	$9.22B
Gross Margin	79.36%

Recent GILD Insider Trades

Dickinson Andrew D sold 3.00K (~$396.81K) on May 15, 2026.
Mercier Johanna sold 7.75K (~$1.01M) on May 15, 2026.
Mercier Johanna sold 11.18K (~$1.47M) on May 15, 2026.
Mercier Johanna sold 8.37K (~$1.11M) on May 15, 2026.
Mercier Johanna sold 700 (~$92.93K) on May 15, 2026.

Latest GILD News

Gilead Sciences Prices $3 Billion Notes at 4.25%-4.90% Across Four Maturities — May 15, 2026
Gilead Tops Q1 Estimates with 12% HIV, 28% Trodelvy Sales Growth — May 8, 2026
Gilead Cuts Full-Year Guidance, Expects Loss on Acquired R&D Charges — May 7, 2026
California High Court Weighs Gilead’s Liability to 24,000 HIV Patients Over TAF — May 6, 2026
Gilead to Expand ADC Pipeline with $5 Billion Tubulis Deal, Shares Up 1.97% — Apr 8, 2026

GILD Analyst Consensus

22 analysts cover GILD: 0 strong buy, 18 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $159.83.

Common questions about GILD

Who is trading GILD stock inside the company?: Recent GILD insider activity includes Dickinson Andrew D sold 3.00K, Mercier Johanna sold 7.75K, Mercier Johanna sold 11.18K, Mercier Johanna sold 8.37K, and Mercier Johanna sold 700. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for GILD?: Yes. Rallies tracks GILD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is GILD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GILD. It does not provide personalized investment advice.